American Society of Hematology

Fig. 8.

$Fig. 8. Clonogenic assay of CD34+FLT3+, CD34+FLT3−, and CD34+ cells performed in IL-1, IL-3, IL-6, G-CSF, GM-CSF, SCF (each added at 10 ng/mL) and 4 IU of erythropoietin. The number of myeloid (CFU-GM) and erythroid (BFU-E) clonogenic cells was determined at day 14 after culture of 500 cells of each phenotpye. The graph shows the mean (± SEM) CFU-GM and BFU-E/1,000 input cells from culture of four normal BM samples. BFU-E were enriched in the CD34+FLT3− fraction as compared with the CD34+FLT3+ cells (P = .0014) or total CD34+ cells (P = .009). The incidence of CFU-GM was equivalent in each fraction.$

Clonogenic assay of CD34⁺FLT3⁺, CD34⁺FLT3⁻, and CD34⁺ cells performed in IL-1, IL-3, IL-6, G-CSF, GM-CSF, SCF (each added at 10 ng/mL) and 4 IU of erythropoietin. The number of myeloid (CFU-GM) and erythroid (BFU-E) clonogenic cells was determined at day 14 after culture of 500 cells of each phenotpye. The graph shows the mean (± SEM) CFU-GM and BFU-E/1,000 input cells from culture of four normal BM samples. BFU-E were enriched in the CD34⁺FLT3⁻ fraction as compared with the CD34⁺FLT3⁺ cells (P = .0014) or total CD34⁺ cells (P = .009). The incidence of CFU-GM was equivalent in each fraction.

This Feature Is Available To Subscribers Only